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Editorial on the Research Topic
Immune Checkpoint Molecules and Cancer Immunotherapy
On October 2nd, we experienced with great enthusiasm that the 2018 Nobel Prize in the Medicine
and Physiology goes to the fathers of check-point molecules CTLA-4 and PD-1 James P. Allison
and Tasuku Honjo “for their discovery of cancer therapy by inhibition of negative immune
regulation”(1, 2). This Nobel Prize assignment was a great note for us as guest editors of the special
issue “Immune Checkpoint Molecules and Cancer Immunotherapy.” Hence, this topic is not just
in vogue but represents an enormous important field of translational cancer immunology. The
discovery of the checkpoint molecules CTLA-4 and PD-1 stimulated pharma industry to develop
specific inhibitors for cancer treatments, encouraging many scientists and clinicians to further
explore this field (3, 4).We have witnessed a real success! Especially about themalignantmelanoma,
where during more than 30 years we saw no progress in the treatment of this tremendous disease
(5–7). Meanwhile, inhibitors of checkpoint molecules and their receptors are approved for the
treatment of different malignancies and there are impressive case reports of patients (8).
But the way is still stony. During the experience with immunotherapeutic drugs based on
targeting of immune checkpoint molecules, many questions, and problems arose. First, not all
cancer types as well as not all patients, tested in immunotherapeutic clinical trials, were sensitive
to the treatment. Second, it is still not clear how we can monitor the therapy successes. Are there
some biomarkers to predict the response to therapy? How can the expression of these immune
checkpoint molecules be modulated or influenced? What is the impact of combination of the
immune checkpoint molecule therapy with a conventional cancer treatment? Undoubtedly, these
and other questions require further intensive research. Therefore, we announced last year this
special issue by Frontiers Immunology. The main aim was to collect novel findings from scientists
and clinicians involved in basic research on immune checkpoints as well as in translational studies
investigating the use of checkpoint inhibitors in immunotherapy in experimental settings.
As mentioned before, not all cancer types tested in immunotherapeutic trials with checkpoint
molecule inhibitors had a benefit from such a therapy. One of these exceptions is the pancreatic
adenocarcinoma (PDAC). This extremely severe cancer did not respond to the immune checkpoint
inhibition treatment. Kabacaoglu et al. attempted to elucidate this problem in the review “Immune
Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future
Options.” The authors shed light on the immune escape mechanisms allowing PDAC to avoid the
effect of immune checkpoint inhibition. Further more they discussed possibilities to potentially
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improve outcome of such immunotherapy in PDAC. In this line,
we are pleased to introduce results of the original research of
Rataj et al. “PD1-CD28 Fusion Protein Enables CD4+ T Cell
Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer
and Non-hodgkin Lymphoma,” where intriguing data showing a
potential for such fusion to overcome the immune suppression
due to PD1-PD-L1 axe. Since the authors used two very different
cancer models, the results of this study represent a generalized
significance.
Importance of crosstalk between immune checkpoint
molecules and cellular immunosuppression gets as well
increasingly more consideration. About that, the review of
Weber et al. “Myeloid-Derived Suppressor Cells Hinder the
Anti-Cancer Activity of Immune Checkpoint Inhibitors” shed light
on a specific immunosuppressive cell population—myeloid-
derived suppressor cells, which appear to affect the suppressive
potential of immune checkpoint molecules. The authors
profoundly discussed the possibility to combine targeting of both
immunosuppressive components. This could be valid not only
for the malignant melanoma, but also in other cancers, especially
in the prostate adenocarcinoma which is highlighted in the
review of Elia et al. “Immune Checkpoint-Mediated Interactions
Between Cancer and Immune Cells in Prostate Adenocarcinoma
and Melanoma.”
What is new about biomarkers of response to therapy
with inhibitors of the immune checkpoint molecules? Kristina
Buder-Bakhaya and Jessica Hassel from Heidelberg dealt very
intensely with this topic in the review “Biomarkers for Clinical
Benefit of Immune Checkpoint Inhibitor Treatment – A Review
From the Melanoma Perspective and Beyond.” The authors
thoroughly aggregated the current status of prognostic and
predictive biomarkers, used in immune checkpoint inhibition
for melanoma and other malignances. They concluded that
several possible biomarkers for response to such therapy are now
available and should be validated in large clinical trials. Some
unexpected relations to the regulatory molecules came as well
out in this issue. De Assis et al. could trace a link between
circadian clock genes (!) and the aforesaid molecules in their
report “Expression of the Circadian Clock gene BMAL1 Positively
Correlates With Antitumor Immunity and Patient Survival in
Metastatic Melanoma.” Besides, the gene BMAL1 was found to
be associated with an increase in the antitumor immune response
but also with the clinical benefit for melanoma patients treated
with checkpoint molecule inhibitors; in other words it could
be a potential treatment biomarker. What is beyond? In this
article collection we are pleased to welcome three original studies,
which enlarge the circle of potential biomarkers also apart from
malignant melanoma. An interesting report “Indoleamine 2,3-
Dioxygenase Expression Pattern in the Tumor Microenvironment
Predicts Clinical Outcome in early Stage cervical Cancer” was
received from the group of Heeren et al. from Amsterdam.
The authors claimed that indoleamine dioxygenase can be
recognized as a real immune checkpoint molecule. Moreover,
they conveniencely demonstrated that a marginal expression
of this enzyme predicts a favorable outcome for patients with
cervical cancer, making this protein a potential inhibitory
target as well as a prognostic biomarker. Another impressive
study came from Manjarrez-Orduño et al. “Circulating T Cell
Subpopulation Correlate With Immune Responses at the Tumor
Site and Clinical Response to PD-1 Inhibition in Non-Small
Cell Lung Cancer.” The title of the paper is self-describing
and this work opens new avenues in the field of potential
blood biomarkers. In addition to that, head and neck cancer is
represented in this special issue. A case report from Qatar by
Merhi et al. “Squamous Cell Carcinomas of the Head and Neck
Cancer Response to Programmed Cell Death Protein-1 Targeting
and Differential Markers” introduces a patient suffering from this
cancer, who was treated with Nivolumab. The authors indicated
that in this case a defined cytokine/chemokine profile might be
useful for identifying a response to PD-1 inhibition.
The next series of papers is devoted to the matter of regulation
of checkpoint molecule expression. An amiable perspective on
the post-transcriptional regulation of CD73/NT5E is delineated
by the group of Kordaß et al. from DKFZ Heidelberg in
the paper “Controlling the Immune Suppression: Transcription
Factors and MicroRNAs Regulating CD73/NT5E.” They reviewed
all contemporary literature concerning this point and highlighted
the significance of miRNA involved in the regulation of this
checkpoint molecule expression. With respect to transcription
factors, Bhat et al. from India showed in their paper “Checkpoint
Blockade Rescues the Repressive Effect of Histone Deacetylases
Inhibitors on γ δ T cell Function” that Eomes and T-bet could
be potential regulators of PD-1 expression. The regulation of
PD-L1 expression was assessed in the work of Bazhin et al.
“Interferon-α Up-Regulates the Expression of PD-L1 Molecules
on Immune Cells Through STAT3 and p38 Signaling.” The
authors observed that the type I interferon is indeed involved
in the regulation of PD-L1 expression through the above-
mentioned transcription factors. A very unorthodox point of
view presented by Wang et al. devoted to the gut microbiota
in context of immune checkpoint molecules. In their review
“Modulation of Gut Microbiota: A Novel Paradigm of Enhancing
the Efficacy of Programmed death-1 and Programmed death
Ligand-1 Blockade Therapy” the authors thoughtfully discussed
the influence of gut microbiota on blocking of PD1-PD-L1
axis.
The authors leaded by Yan et al. were concerned with the
problems of combining immune checkpoint inhibition with
conventional tumor therapy in the manuscript “Combining
Immune Checkpoint Inhibitors With Conventional Cancer
Therapy.” They reviewed current literature analyzing the impact
of chemo-, radio-, and target therapies on therapeutic effects
of immune checkpoint inhibition and discussed the current
and the future clinical applications of such combination.
Finally, Shevchenko and Bazhin pointed in their work to
an importance of discovery of new potential checkpoints
molecules. They payed attention in their mini-review “Metabolic
Checkpoints: Novel Avenues for Immunotherapy of Cancer”
to so-called metabolic checkpoint molecules which could be
the “new era” of the cancer immunotherapy with checkpoint
inhibition.
Summarizing, the wide spectrum of reviews and original
papers from this issue provides an insight into new research
directions linked to an extremely important topic-immune
Frontiers in Immunology | www.frontiersin.org 2 December 2018 | Volume 9 | Article 2878
Bazhin et al. Checkpoint Molecules and Cancer Immunotherapy
checkpoint molecules in context of cancer immunotherapy.
We wish all readers of this special issue to have an
exciting time to take a close look into a subject of this
compendium.
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